Fact CheckerSign in

NCT05315141Recruiting

Multicenter Cohort Study of AAV in Hunan of China

Multicenter Cohort Study of ANCA-associated Small Vasculitis in Hunan Province of China

Source: ClinicalTrials.gov · Last updated 7 Apr 2022 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.

Status (registry)
Recruiting
Study type
Observational
Enrollment
500 (estimated)
First submitted
16 Mar 2022
Start date
16 Mar 2022
Primary completion date
16 Mar 2027
Lead sponsor
Xiangya Hospital of Central South University
NCT number
NCT05315141

What you commit to

  • Study type: Observational
  • Planned participants: 500
  • From 16 Mar 2022 to the primary completion date, 16 Mar 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Do not agree to sign informed consent

Who the study is looking for

  • Fulfill 2012 criteria of ANCA associated vasculitis and agree to sign informed consent

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Xiangya Hospital
Coordinator of this site? Confirm its status
ChangshaChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.